Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
08.05. | Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase | ||
08.05. | Gilead tees up $11B in new US manufacturing, R&D investments | ||
07.05. | Moderna faces PMCPA audit over 'completely unacceptable' lack of transparency | ||
07.05. | J&J survey finds pace of oncology innovation is overwhelming physicians | ||
07.05. | AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial | ||
07.05. | Xellia to shutter Copenhagen antibiotics plant, dealing a blow to EU reshoring efforts | ||
07.05. | Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth | ||
06.05. | Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia | ||
06.05. | FDA commissioner Marty Makary taps Vinay Prasad to head up CBER | ||
06.05. | Neurocrine holds on to branded tardive dyskinesia push with help from Wilson Phillips star | ||
06.05. | 'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge | ||
06.05. | Trump signs executive order to boost US drug manufacturing amid threat of tariffs | ||
06.05. | Incyte, Novartis agree to settle long-running Jakafi royalty dispute just before trial | ||
06.05. | Havas Life opens Dubai office to serve 'thriving' Middle East and North Africa region | ||
06.05. | AstraZeneca debuts $300M cell therapy manufacturing facility in Maryland | ||
05.05. | Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing head | ||
05.05. | US net drug spending surged 11.4% last year, boosted by obesity and oncology meds: IQVIA | ||
05.05. | AbbVie's Skyrizi retakes top TV ad spending spot for the first time all year | ||
05.05. | BioNTech, gearing up for cancer drug approval filing, works to diversify supply base | ||
02.05. | AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion | ||
02.05. | BMS scales back at former Novartis plant, shifting cell therapy vector production to MA | ||
02.05. | Almirall, Biofrontera encourage sun protection in actinic keratosis social media challenge | ||
02.05. | Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row | ||
02.05. | As Amgen's trio of Horizon drugs disappoints, execs urge analysts to give them more time | ||
02.05. | Regulatory tracker: AbbVie's Rinvoq scores 9th FDA nod, this time in GCA |